EP 1635862 A1 20060322 - PEPTIDES DERIVED FROM THE PROTEIN MMP-2, AND THE USE THEREOF IN ANTITUMORAL IMMUNOTHERAPY
Title (en)
PEPTIDES DERIVED FROM THE PROTEIN MMP-2, AND THE USE THEREOF IN ANTITUMORAL IMMUNOTHERAPY
Title (de)
MMP-2 PEPTIDFRAGMENTE UND DEREN VERWENDUNG IN IMMUNOTHERAPIE GEGEN KREBS
Title (fr)
PEPTIDES DERIVES DE LA PROTEINE MMP-2 ET LEUR UTILISATION EN IMMUNOTHERAPIE ANTITUMORALE
Publication
Application
Priority
- FR 2004001585 W 20040624
- FR 0307659 A 20030625
Abstract (en)
[origin: WO2005000342A1] The invention relates to peptides forming epitopes T of the antigen MMP-2, presented by MHC class I. Said peptides can especially be used in antitumoral immunotherapy.
IPC 1-7
A61K 38/48; C07K 4/12; A61K 39/00; A61K 38/08; A61K 48/00; C12N 15/11; C12N 5/10; G01N 33/68; A61P 35/00
IPC 8 full level
A61P 35/00 (2006.01); A61P 37/04 (2006.01); C12N 5/0783 (2010.01); C12N 5/0784 (2010.01); C12N 9/64 (2006.01); C12N 15/57 (2006.01); A61K 35/12 (2015.01); A61K 39/00 (2006.01)
CPC (source: EP US)
A61P 35/00 (2018.01 - EP); A61P 37/04 (2018.01 - EP); C12N 5/0636 (2013.01 - EP US); C12N 9/6491 (2013.01 - EP US); A61K 2035/124 (2013.01 - EP US); A61K 2039/5154 (2013.01 - EP US); A61K 2039/5156 (2013.01 - EP US); A61K 2039/5158 (2013.01 - EP US); A61K 2039/5256 (2013.01 - EP US); A61K 2039/53 (2013.01 - EP US); A61K 2039/57 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
FR 2856598 A1 20041231; FR 2856598 B1 20051028; CA 2529943 A1 20050106; EP 1635862 A1 20060322; JP 2007520198 A 20070726; US 2007264275 A1 20071115; US 7629439 B2 20091208; WO 2005000342 A1 20050106
DOCDB simple family (application)
FR 0307659 A 20030625; CA 2529943 A 20040624; EP 04767441 A 20040624; FR 2004001585 W 20040624; JP 2006516321 A 20040624; US 56195104 A 20040624